ArticleArchives of pathology & laboratory medicine2020
Comparative Performance of High-Risk Human Papillomavirus RNA and DNA In Situ Hybridization on College of American Pathologists Proficiency Tests.
Abstract readComparative Study
In one paragraph
Article in Archives of pathology & laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline.Head and neck pathology · 2025Guideline
- Improved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing.Leukemia · 2026Article
- Optimization of RNAscope for HPV mRNA detection in liquid-based cervical cytology samples.Frontiers in oncology · 2026Article
- Review
- Sexually transmitted human papillomavirus and related sequelae.Clinical microbiology reviews · 2025Review
- Human Papillomavirus-Associated Oral Epithelial Dysplasia: Report of 5 Illustrative Cases from Latin America.Head and neck pathology · 2023Article
- Clinicopathologic characterization of cervical metastasis from an unknown primary tumor: a multicenter study in Korea.Journal of pathology and translational medicine · 2023Article
- Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.Cancer research communications · 2022Article
- RB1, p16, and Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma.Head and neck pathology · 2021Article
- Application of the Roche Cobas® HPV 4800 in Formalin-Fixed, Paraffin-Embedded Samples for Head and Neck Squamous Cell Carcinomas.Head and neck pathology · 2021Article
- Quantitative assessment of p16 expression in FNA specimens from head and neck squamous cell carcinoma and correlation with HPV status.Cancer cytopathology · 2021Article
- Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization.Journal of pathology and translational medicine · 2020Article
- HPV Detection in Head and Neck Squamous Cell Carcinomas: What Is the Issue?Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Elaine S KeungFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Rhona J SouersFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Julia A BridgeFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
William C FaquinFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Rondell P GrahamFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Meera R HameedFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
James S LewisFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Jason D MerkerFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Patricia VasalosFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Joel T MoncurFrom the Department of Pathology and Laboratory Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Keung); Biostatistics Department (Ms Souers) and Proficiency Testing (Ms Vasalos), College of American Pathologists, Northfield, Illinois; Division of Molecular Pathology, The Translational Genomics Research Institute (TGen)/Ashion Laboratory, Phoenix, Arizona, and the Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha (Dr Bridge); the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Faquin); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Graham); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Hameed); the Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Dr Lewis); the Departments of Pathology and Laboratory Medicine & Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill (Dr Merker); and Office of the Director, The Joint Pathology Center, Silver Spring, Maryland (Dr Moncur).
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MStrategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI MEMPEL, THORSTEN ROMAN · 2019 to 2023
$8.4MNCI NIH HHS P01 CA240239NCI NIH HHS P30 CA008748
Abstract
CONTEXT.—: Detection of high-risk human papillomavirus (HR-HPV) in squamous cell carcinoma is important for classification and prognostication. In situ hybridization (ISH) is a commonly used HR-HPV-specific test that targets viral RNA or DNA. The College of American Pathologists (CAP) provides proficiency testing for laboratories performing HR-HPV ISH. OBJECTIVE.—: To compare the analytical performance of RNA- and DNA-based ISH methods on CAP HR-HPV proficiency tests. DESIGN.—: Data from the 2016-2018 CAP HPV ISH proficiency testing surveys were reviewed. These surveys consist of well-characterized samples with known status for HR-HPV, including 1 to 2 copies, 50 to 100 copies, 300 to 500 copies, and no copies of HR-HPV per cell. RESULTS.—: Ninety-five participants submitted 1268 survey results from 20 cores. Overall, RNA ISH had a significantly higher percentage of correct responses than DNA ISH: 97.4% (450 of 462) versus 80.6% (650 of 806) ( CONCLUSIONS.—: An assessment of CAP HR-HPV proficiency test performance indicates that RNA ISH shows significantly higher accuracy than DNA ISH owing to higher analytical sensitivity of RNA ISH in tumors with low (1-2 copies per cell) to intermediate (50-100 copies per cell) HR-HPV viral copy numbers. These data support the use of RNA over DNA ISH in clinical laboratories that perform HR-HPV testing as part of their testing algorithms.
Indexed as
Carcinoma, Squamous CellDNA, ViralHead and Neck NeoplasmsHumansIn Situ HybridizationLogistic ModelsMolecular Diagnostic TechniquesMultivariate AnalysisPapillomaviridaePapillomavirus InfectionsPathologistsRNA, ViralSensitivity and SpecificitySurveys and QuestionnairesDNA, ViralRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.